1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Luo, Jing ^a   Wen, Hongyan ^a   Guo, Hui ^a   Cai, Qi ^b   Li, Shuangtian ^c   Li, Xiaofeng ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 17; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ARTHRITIS, RHEUMATOID; BLOOD; BONE; CARTILAGE; DRUG EFFECTS; GENE EXPRESSION REGULATION; INJURIES; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; DRUG EFFECT; INJURY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BONE AND BONES; CALCITRIOL; CARTILAGE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-4; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANK LIGAND; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877997274     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/101805     Document Type: Article

References (36)

1. Walsh N. C., Crotti T. N., Goldring S. R., Gravallese E. M., Rheumatic diseases: the effects of inflammation on bone. Immunological Reviews 2005 208 228 251 2-s2.0-28544448518 (Pubitemid 41746396)
2. Stewart A., Mackenzie L. M., Black A. J., Reid D. M., Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology 2004 43 12 1561 1564 2-s2.0-10444241015 10.1093/rheumatology/keh385 (Pubitemid 39642583)
3. Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation. Nature 2003 423 6937 337 342 2-s2.0-0037673945 10.1038/nature01658 (Pubitemid 40852708)
4. Jones D. H., Kong Y. Y., Penninger J. M., Role of RANKL and RANK in bone loss and arthritis. Annals of the Rheumatic Diseases 2002 61 2 ii32 ii39 2-s2.0-0036838918 (Pubitemid 35221710)
5. Adamopoulos I. E., Bowman E. P., Immune regulation of bone loss by Th17 cells. Arthritis Research and Therapy 2008 10 5, article 225 2-s2.0-60549110257 10.1186/ar2502
6. Takayanagi H., Osteoimmunology and the effects of the immune system on bone. Nature Reviews Rheumatology 2009 5 667 676 10.1038/nrrheum.2009.217
7. Horwood N. J., Kartsogiannis V., Quinn J. M. W., Romas E., Martin T. J., Gillespie M. T., Activated T lymphocytes support osteoclast formation in vitro. Biochemical and Biophysical Research Communications 1999 265 1 144 150 2-s2.0-0033547343 10.1006/bbrc.1999.1623
8. + T cells. European Journal of Immunology 2001 31 7 2179 2188 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X (Pubitemid 32640735)
9. Dai S. M., Matsuno H., Nakamura H., Nishioka K., Yudoh K., Interleukin-18 enhances monocyte tumor necrosis factor α and interleukin-1 β production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis and Rheumatism 2004 50 2 432 443 2-s2.0-1042267244 10.1002/art.20064 (Pubitemid 38198827)
10. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M. T., Martin T. J., Suda T., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. Journal of Clinical Investigation 1999 103 9 1345 1352 10.1172/JCI5703 (Pubitemid 29218305)
11. Hofbauer L. C., Lacey D. L., Dunstan C. R., Spelsberg T. C., Riggs B. L., Khosla S., Interleukin-1 β and tumor necrosis factor- α but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999 25 3 255 259 2-s2.0-0032588998 10.1016/S8756-3282(99)00162-3 (Pubitemid 29406050)
12. O'Brien C. A., Gubrij I., Lin S. C., Saylors R. L., Manolagas S. C., STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF- B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. Journal of Biological Chemistry 1999 274 27 19301 19308 2-s2.0-0033516661 10.1074/jbc.274.27.19301 (Pubitemid 29314134)
13. Boyce B. F., Xing L., Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research and Therapy 2007 9 supplement 1, article S1 2-s2.0-34548454049 10.1186/ar2165 (Pubitemid 351803968)
14. Nielsen H. K., Brixen K., Kassem M., Mosekilde L., Acute effect of 1,25-dihydroxyvitamin D3, prednisone, and 1,25-dihydroxyvitamin D3 plus prednisone on serum osteocalcin in normal individuals. Journal of Bone and Mineral Research 1991 6 5 435 441 2-s2.0-0025739737
15. Cippitelli M., Santoni A., Vitamin D3: a transcriptional modulator of the interferon-gamma gene. European Journal of Immunology 1998 28 10 3017 3030 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.0. CO;2-6 (Pubitemid 28470247)
16. Manolagas S. C., Werntz D. A., Tsoukas C. D., Provvedini D. M., Vaughan J. H., 1,25-dihydroxyvitamin D3 receptors in lymphocytes from patients with rheumatoid arthritis. Journal of Laboratory and Clinical Medicine 1986 108 6 596 600 2-s2.0-0023032299 (Pubitemid 17186613)
17. Wessels J. A. M., Huizinga T. W. J., Guchelaar H. J., Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 2008 47 3 249 255 2-s2.0-39449121672 10.1093/rheumatology/kem279 (Pubitemid 351267187)
18. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G., The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988 31 3 315 324 2-s2.0-0023945481 (Pubitemid 18091653)
19. Kremer J. M., Methotrexate therapy in the treatment of rheumatoid arthritis. Rheumatic Disease Clinics of North America 1989 15 3 533 556 (Pubitemid 19207146)
20. Teitelbaum S. L., Bone resorption by osteoclasts. Science 2000 289 5484 1504 1508 2-s2.0-0034284970 10.1126/science.289.5484.1504
21. Maruotti N., Grano M., Colucci S., d'Onofrio F., Cantatore F. P., Osteoclastogenesis and arthritis. Clinical and Experimental Medicine 2011 11 3 137 145 10.1007/s10238-010-0117-2
22. Khosla S., Minireview: The OPG/RANKL/RANK system. Endocrinology 2001 142 12 5050 5055 2-s2.0-0035206443 10.1210/en.142.12.5050 (Pubitemid 33131929)
23. Kim H. R., Lee S. H., Kim H. Y., Elevated serum levels of soluble receptor activator of nuclear factors- B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006 45 10 1197 1200 2-s2.0-33749598017 10.1093/rheumatology/kel072 (Pubitemid 44542059)
24. Zhang R., Naughton D. P., Vitamin D in health and disease: current perspectives. Nutrition Journal 2010 9 1, article 65 2-s2.0-78649800662 10.1186/1475-2891-9-65
25. Moro J. R., Iwata M., von Andriano U. H., Vitamin effects on the immune system: vitamins A and D take centre stage. Nature Reviews Immunology 2008 8 685 698 10.1038/nri2378
26. Pedersen L. B., Nashold F. E., Spach K. M., Hayes C. E., 1,25-Dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. Journal of Neuroscience Research 2007 85 11 2480 2490 2-s2.0-34547630883 10.1002/jnr.21382 (Pubitemid 47204762)
27. Adorini L., Penna G., Control of autoimmune diseases by the vitamin D endocrine system. Nature Clinical Practice Rheumatology 2008 4 404 412 10.1038/ncprheum0855
28. Smolders J., Thewissen M., Peelen E., Menheere P., Tervaert J. W. C., Damoiseaux J., Hupperts R., Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE 2009 4 8 2-s2.0-68949140898 10.1371/journal.pone.0006635 e6635
29. Royal W., Mia Y., Li H., Naunton K., Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. Journal of Neuroimmunology 2009 213 1-2 135 141 2-s2.0-68049101203 10.1016/j.jneuroim.2009.05.012
30. Suda T., Ueno Y., Fujii K., Shinki T., Vitamin D and bone. Journal of Cellular Biochemistry 2003 88 2 259 266 2-s2.0-0037302257 10.1002/jcb.10331 (Pubitemid 36119896)
31. Zhao X. Y., Ly L. H., Peehl D. M., Feldman D., Induction of androgen receptor by α25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999 140 3 1205 1212 2-s2.0-0032937372 (Pubitemid 29104222)
32. Lee C. K., Lee E. Y., Chung S. M., Mun S. H., Yoo B., Moon H. B., Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor B, osteoprotegerin, and receptor activator of nuclear factor B ligand. Arthritis and Rheumatism 2004 50 12 3831 3843 2-s2.0-10444273254 10.1002/art.20637 (Pubitemid 39643930)
33. Kirkham B. W., Lassere M. N., Edmonds J. P., Juhasz K. M., Bird P. A., Lee C. S., Shnier R., Portek I. J., Synovial membrahe cytokine expression is predictive of joint damage progression in rheumatoid arthritis a two-year prospective study(the damage study cohort). Arthritis and Rheumatism 2006 54 4 1122 1131 10.1002/art.21749 (Pubitemid 43672925)
34. Hashizume M., Hayakawa N., Mihara M., IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- α and IL-17. Rheumatology 2008 47 11 1635 1640 2-s2.0-54449101331 10.1093/rheumatology/ken363
35. Tyagi A. M., Srivastava K., Mansoori M. N., Trivedi R., Chattopadhyay N., Singh D., Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS ONE 2012 7 9 e44552 10.1371/journal.pone.0044552
36. Deuell K. A., Callegari A., Giachelli C. M., Rosenfeld M. E., Scatena M., RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF- α Journal of Vascular Research 2012 49 6 510 521 10.1159/000341216